TCGA-AR-A1AV-01A-21R-A12P-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 62
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.510
- TGF_BETA_SIGNALING+0.320
- ESTROGEN_RESPONSE_EARLY+0.310
- MITOTIC_SPINDLE+0.280
- UV_RESPONSE_DN+0.260
- ANDROGEN_RESPONSE+0.190
- ESTROGEN_RESPONSE_LATE+0.170
- PI3K_AKT_MTOR_SIGNALING+0.170
- NOTCH_SIGNALING+0.160
- HEME_METABOLISM+0.150
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.500
- INTERFERON_ALPHA_RESPONSE-0.440
- INTERFERON_GAMMA_RESPONSE-0.430
- KRAS_SIGNALING_DN-0.370
- IL6_JAK_STAT3_SIGNALING-0.360
- HEDGEHOG_SIGNALING-0.290
- INFLAMMATORY_RESPONSE-0.290
- PANCREAS_BETA_CELLS-0.270
- SPERMATOGENESIS-0.210
- IL2_STAT5_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A08O-01A-21R-A056-07 | — | B | 0.840 |
| 2 | TCGA-D8-A1X7-01A-11R-A14M-07 | — | B | 0.829 |
| 3 | TCGA-AN-A0FZ-01A-11R-A034-07 | — | B | 0.805 |
| 4 | TCGA-A8-A0AB-01A-11R-A034-07 | — | B | 0.785 |
| 5 | TCGA-C8-A26Z-01A-11R-A16F-07 | — | B | 0.780 |
| 6 | TCGA-BH-A0E7-01A-11R-A034-07 | — | B | 0.773 |
| 7 | TCGA-E2-A15T-01A-11R-A115-07 | — | B | 0.757 |
| 8 | TCGA-AR-A2LK-01A-11R-A180-07 | — | B | 0.752 |
| 9 | TCGA-D8-A1XS-01A-11R-A14M-07 | — | B | 0.750 |
| 10 | TCGA-A8-A085-01A-11R-A00Z-07 | — | B | 0.749 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.510 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.310 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.280 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.160 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| MYC_TARGETS_V2 | 0.150 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.110 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.090 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.080 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.060 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.040 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.040 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.040 | Inavolisib | — uncovered |